{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=metformin+placebo&page=3", "query": { "intervention": "metformin placebo", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 421, "total_pages": 43, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=metformin+placebo&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=metformin+placebo&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T03:37:01.151Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01452451", "title": "Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "HM11260C", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hanmi Pharmaceutical Company Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 72, "start_date": "2011-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-08-09", "last_synced_at": "2026-10-05T03:37:01.151Z", "location_count": 1, "location_summary": "Ohio City, Ohio", "locations": [ { "city": "Ohio City", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01452451" }, { "nct_id": "NCT01241448", "title": "A Study of LY2409021 in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "LY2409021", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 263, "start_date": "2011-01", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2018-04-24", "last_synced_at": "2026-10-05T03:37:01.151Z", "location_count": 18, "location_summary": "Burbank, California • Concord, California • Fresno, California + 15 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Lakewood", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01241448" }, { "nct_id": "NCT01664624", "title": "Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Roflumilast", "type": "DRUG" }, { "name": "Alogliptin", "type": "DRUG" }, { "name": "Exenatide", "type": "DRUG" }, { "name": "Placebo to roflumilast", "type": "DRUG" }, { "name": "Placebo to alogliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 40, "start_date": "2012-07", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2017-02-01", "last_synced_at": "2026-10-05T03:37:01.151Z", "location_count": 2, "location_summary": "Chula Vista, California • Orlando, Florida", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01664624" }, { "nct_id": "NCT03136484", "title": "Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Semaglutide", "type": "DRUG" }, { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Placebo (canagliflozin)", "type": "DRUG" }, { "name": "Placebo (semaglutide)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 788, "start_date": "2017-03-15", "completion_date": "2018-11-16", "has_results": true, "last_update_posted_date": "2020-01-21", "last_synced_at": "2026-10-05T03:37:01.151Z", "location_count": 57, "location_summary": "Anaheim, California • La Mesa, California • Los Angeles, California + 43 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Montclair", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03136484" }, { "nct_id": "NCT01664247", "title": "The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin degludec", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "liraglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 346, "start_date": "2012-10-01", "completion_date": "2013-12-31", "has_results": true, "last_update_posted_date": "2017-09-25", "last_synced_at": "2026-10-05T03:37:01.151Z", "location_count": 67, "location_summary": "Anaheim, California • Concord, California • Escondido, California + 59 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01664247" }, { "nct_id": "NCT04156750", "title": "A Study of LY3556050 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "LY3556050", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Iohexol", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 34, "start_date": "2019-11-20", "completion_date": "2020-08-03", "has_results": false, "last_update_posted_date": "2020-08-19", "last_synced_at": "2026-10-05T03:37:01.151Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04156750" }, { "nct_id": "NCT00749190", "title": "BI 10773 add-on to Metformin in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "BI 10773", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 495, "start_date": "2008-08", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-06-13", "last_synced_at": "2026-10-05T03:37:01.151Z", "location_count": 19, "location_summary": "Chula Vista, California • Mission Viejo, California • Pasadena, California + 15 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Spring Valley", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00749190" }, { "nct_id": "NCT07475546", "title": "Combination Gerotherapeutic Interventions for Healthspan Improvement", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Healthspan Improvement", "Aging", "Longevity" ], "interventions": [ { "name": "Rapamycin", "type": "DRUG" }, { "name": "Naltrexone", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "NAD+", "type": "DRUG" }, { "name": "GSH", "type": "DRUG" }, { "name": "Infinite Supplement", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo/control", "type": "DRUG" }, { "name": "B12", "type": "DIETARY_SUPPLEMENT" }, { "name": "Intervention: Guided Meditation Program", "type": "BEHAVIORAL" }, { "name": "Control: Podcast Listening Activity", "type": "BEHAVIORAL" }, { "name": "Control: Standard Exercise Regimen", "type": "BEHAVIORAL" }, { "name": "Intervention: Structured Exercise Program", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT", "BEHAVIORAL" ], "sponsor": "AgelessRx", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "60 Years to 80 Years" }, "enrollment_count": 30, "start_date": "2025-07-23", "completion_date": "2026-04", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-10-05T03:37:01.151Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07475546" }, { "nct_id": "NCT02405260", "title": "Add Glucokinase Activator to Target A1c", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "TTP399 400 mg", "type": "DRUG" }, { "name": "TTP399 800 mg", "type": "DRUG" }, { "name": "Sitagliptin 100 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "vTv Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 190, "start_date": "2015-03", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2017-02-10", "last_synced_at": "2026-10-05T03:37:01.151Z", "location_count": 20, "location_summary": "Mesa, Arizona • Tuscon, Arizona • Canoga Park, California + 16 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tuscon", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02405260" }, { "nct_id": "NCT01512979", "title": "Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "metformin", "type": "DRUG" }, { "name": "linagliptin", "type": "DRUG" }, { "name": "metformin placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2012-01", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2014-05-20", "last_synced_at": "2026-10-05T03:37:01.151Z", "location_count": 29, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Chino, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Chino", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01512979" } ] }